Movement Alert|Legend Biotech Falls 5.29% in Regular Trading, Evercore ISI Downgrade Adds to Post-Earnings Pressure

Market Focus11-17

On November 17, Legend Biotech fell 5.29% in Regular Trading, trading at $16.595 per share, with turnover of $20.5456 million.

The move was linked to continued post-earnings selling pressure after Evercore ISI downgraded the stock to In Line and set a $20 price target, extending a broader wave of analyst target cuts following the company’s latest quarterly report.

In its recent results, Legend Biotech reported third-quarter net profit of $51.7 million, reversing a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations near $361.5 million. After the report, RBC, Morgan Stanley, Oppenheimer and Barclays also lowered price targets, indicating a more cautious near-term stance on growth and valuation despite solid product sales momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment